TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2017

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

Won Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.